Telix Pharmaceuticals Ltd
corporate_fare Company Profile
Telix Pharmaceuticals Ltd (OTC:TLPPF) is a publicly traded company in the Healthcare sector. Wiseek has independently scored 3 items for TLPPF at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-04-14, rated 8/10. Across its 3 most recent items scored 7 or higher, the top rating is 9/10, with 3 rated 8 or above. Recent SEC coverage for TLPPF spans 6-K.
Recent high-impact activity:
- Telix Upsizes Convertible Bond Offering to US$600M with 37.5% Conversion Premium
- Telix Pharmaceuticals Refinances $550M Convertible Bonds at Premium
- Telix Pharmaceuticals Secures Major Radiopharma Collaboration with Regeneron, Including $40M Upfront
Short Interest & Short Volume
FINRA reported short interest of 4,564,828 shares in TLPPF as of the September 15, 2026 settlement, a 2.0% decrease from the prior period. On October 2, 2026, 97.2% of TLPPF volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Insider Transactions
TLPPF files as a Foreign Private Issuer (FPI). Under SEC Exchange Act Section 16(a), officers, directors, and 10% owners of FPIs are exempt from Form 4 insider-transaction reporting requirements. Comparable disclosures, when applicable, appear in the company's Form 20-F (annual) or Form 6-K (interim) filings on SEC EDGAR.